Tarsus Pharmaceuticals, Inc. has grown revenue 265% a year over three years and 61% a year over five. Revenue growth, 3-year annual rate: +265% (Biotechnology median +17%). Revenue growth, 5-year rate: +61%, growth has picked up over the last three years. Years of annual history on file: 8, FY2018 to FY2025, as filed.

TARSTarsus Pharmaceuticals, Inc.

Healthcare

$73.14+33% 1Y

$73.14

$55.2652 weeks$90.81

Is it growing?

Good

Growing: revenue growing +105% year on year and operating margin widening (+27.9 points).

2 good, 1 without data

Revenue trend+105% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +61% a year.

Margin direction+27.9 points operating

Trailing-twelve-month operating margin, -8.2% now against -36.1% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 1% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is TARS growing?

Tarsus Pharmaceuticals, Inc. has grown revenue 265% a year over three years and 61% a year over five.

+265%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +61%
Revenue growth, 5-year rate · +265% over three · growth has picked up over the last three years
Years of annual history on file: 8
Years of annual history on file · FY2018 to FY2025, as filed

Details›